Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | RARB | P10826 | 4/20 | 0.55 |
| ▸ | RARG | P13631 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.55 |
| ▸ | GOT1 | P17174 | 1/20 | 0.55 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9126386 | 0.91 | RARA (0.58) | RARAKMT2ARARBRARGLMNA | |
| SCHEMBL5084769 | 0.90 | RARA (0.57) | RARAKMT2ARARBRARGLMNA | |
| SCHEMBL8087948 | 0.89 | RARA (0.43) | RARAKMT2ARARBRARGLMNA | |
| SCHEMBL5081692 | 0.89 | RARA (0.56) | RARAKMT2ARARBRARGLMNA | |
| SCHEMBL9123398 | 0.88 | RARA (0.53) | RARAKMT2ARARBRARGLMNA | |
| SCHEMBL5078191 | 0.87 | RARA (0.67) | RARAKMT2ARARBRARGLMNA | |
| SCHEMBL9128314 | 0.85 | RARA (0.45) | RARAKMT2ARARBRARGLMNA | |
| SCHEMBL8461975 | 0.84 | RARA (0.61) | RARAKMT2ARARBRARGLMNA | |
| SCHEMBL9125752 | 0.83 | RARA (0.62) | RARAKMT2ARARBRARGLMNA | |
| SCHEMBL9127710 | 0.83 | KMT2A (0.57) | RARAKMT2ARARBRARGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| EP-0920312-B1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2004-12-08 | — | — | EP | claimed |
| US-20030073745-A1 | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-04-17 | — | — | US | claimed |
| US-6462064-B1 | SUCH AS 6-(3-(1-ADAMANTYL)-4-METHOXYPHENYL)-2-NAPHTHOIC ACID, 2-(3-(1-ADAMANTYL)-4-METHOXYPHENYL)-5-BENZIMIDAZOLE CARBOXY-LIC ACID, AND 6-(3-(1-ADAMANTYL)-4,5-METHYLENEDIOXYPHENYL)-2-NAPHTHOIC ACID | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2002-10-08 | — | — | US | claimed |
| US-6127415-A | ADAMANTYL DERIVATIVE CONTAINING-RETINOID RELATED COMPOUNDS AS ANTICARCINOGENIC AGENTS; SKIN DISORDERS;COSMETICS; AGING RESISTANCE; ALOPEIA | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-10-03 | — | — | US | claimed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | claimed |
| EP-0409728-B1 | Bi-aromatic esters, process for their preparation and their use in human or animal medicine and in cosmetics | CIRD GALDERMA (FR) | 1995-03-01 | — | — | EP | claimed |
| EP-0465343-B1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CIRD GALDERMA (FR) | 1994-06-15 | — | — | EP | claimed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-0920312-B1 | APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS | GALDERMA RES & DEV (FR) | 2004-12-08 | — | — | EP | disclosed |
| US-5587367-A | SYNERGISTIC EFFECT IN TREATING SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-12-24 | — | — | US | disclosed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | disclosed |
| US-5468897-A | Bi-aromatic esters, a process for their preparation and their use in human or veterinary medicine and in cosmetic compositions | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-11-21 | — | — | US | disclosed |
| EP-0409728-B1 | Bi-aromatic esters, process for their preparation and their use in human or animal medicine and in cosmetics | CIRD GALDERMA (FR) | 1995-03-01 | — | — | EP | disclosed |
| US-5332856-A | Treatment of a dermatologic, rheumatismal, respiratory or ophthalmologic ailment | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1994-07-26 | — | — | US | disclosed |
| US-5200550-A | Administering for dermatologic, rheumatismal, respiratory or ophthalomologic disorders | CENTRE INTERNATIONAL DE RECHERCES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1993-04-06 | — | — | US | disclosed |
| EP-0409728-A2 | Bi-aromatic esters, process for their preparation and their use in human or animal medicine and in cosmetics | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | RARA 1211/4885KMT2A 4590/4885RARB 987/4885 |
| US-20030073745-A1 | Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias | CASP3, BAD, RARA | RARA 3/4885KMT2A 2551/4885RARB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.